Rheumatology Patients & Providers Push For Step Therapy, Workforce Changes

Rheumatology professional and patients visited with 117 legislators and their staffs during the 2019 Advocates for Arthritis event to champion better rheumatology patient care and access.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Legislation & Advocacy Advocacy 101 Advocates for Arthritis RheumPAC Source Type: research

Related Links:

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Biologics & Biosimilars Conditions Crystal Arthritis DMARDs & Immunosuppressives Drug Updates Gout Source Type: research
Last year, Medgadget heard from Noble International about its “smart” training devices that educate patients on safe and effective at-home use of prefilled syringes and autoinjectors. At the time, Joe Reynolds, Research Manager at Noble I...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Pediatrics Source Type: blogs
Are respiratory viral infections associated with an increased risk for the later development of rheumatoid arthritis? A new study investigates.Arthritis Research &Therapy
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Two JAK inhibitors, one recently approved by the FDA, have shown improvements in patients with active RA for whom other therapies have proved ineffective...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Rheumatoid Arthritis drug treatment filgotinib Rheumatoid Arthritis (RA) upadacitinib Source Type: research
AbstractWe read with great interest the letter of Xieet al commenting on our article “Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study”(1).First, the authors suggested classifying Preexisting Autoimmune Diseases (PAD) according to systems, in order to assess if rheumatic disorders were more likely to flare with ICI. Such trend has been reported in other series, like Menzieset al and Leonardiet al, with the limit that the majority of the PAD in their cohort was a rheumatic disorder (n=27, 52% and n=25 (45%) respectively) (2,3).
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: REPLY TO LETTER TO THE EDITOR Source Type: research
AbstractObjectivesTo study the involvement of regulatory T cells (Tregs) expressing tumor necrosis factor ‐αreceptor 2 (TNFR2) incontrol of experimental inflammation and response to treatment in rheumatoid arthritis (RA) and spondyloarthritis (SpA).MethodsThe role of TNFR2 inTregswas exploredusing amultilevel translational approach.Tregstability was evaluatedby analyzing methylation status of thefoxp3locus by bisulfite sequencing. Two models of inflammation (imiquimod ‐induced skin inflammationand delayed type hypersensitivity arthritis, DTHA) were induced inTNFR2‐deficient (TNFR2‐/‐) micewith or without tr...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
AbstractA 35 ‐year‐old African American male with a history of seizures, presented with nausea, vomiting, abdominal pain, thrombocytopenia (platelet count of 48,000) and acute renal failure (BUN/creatinine – 30/5.6). Urinalysis showed mild proteinuria and microscopic hematuria. He was diagnosed with syste mic lupus erythematosus (SLE) on the basis of positive ANA, anti‐dsDNA, arthritis, thrombocytopenia and hypocomplementemia fulfilling 5 of 11 SLE criteria (1). He also was positive for antibodies to cardiolipin, beta2‐glycoprotein‐I and lupus anticoagulant. ADAMTS13 level was lower than norma l b...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: CLINICAL IMAGE Source Type: research
AbstractIn this issue ofArthritis and Rheumatology, McCormick and colleagues report how biologic disease ‐modifying anti‐rheumatic drug (bDMARD) prices increased in Medicare and Medicaid from 2012‐2016.(1) These novel data are gleaned from the Center for Medicare and Medicaid Services’ drug pricing dashboard, which began publicizing year‐over‐year price changes on May 15, 2018.(2) That week , health policy advocates like myself1 perused the dashboard and saw an alarming trend. bDMARD prices appeared to be rising faster in Medicare Part D (the distribution system for drugs that patients self ‐administer) t...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: EDITORIAL Source Type: research
ConclusionPost ‐market drug‐price changes alone account for the majority of recent spending growth for bDMARDs. Policy interventions targeting price increases, particularly under Part D plans, may help mitigate drug financial burdens for public payers and bDMARD recipients.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
S Turkucar, B Makay, H Tatari, E UnsalJournal of Postgraduate Medicine 2019 65(4):233-236 Pigmented villonodular synovitis (PVNS) is a rare benign disorder of a joint which affects its synovium, tendon sheaths and bursas. While most cases of PVNS are adult patients aged between 20-50 years, few afflicted children have also been reported. Clinical signs of PVNS are insidious and non-specific. Pain, swelling and stiffness are the major symptoms. Magnetic Resonance Imaging (MRI) is the best radiological method for diagnosis of PVNS, as the initial X-ray is normal in early phase of disease in most cases. Therefore, diagnosis ...
Source: Journal of Postgraduate Medicine - Category: Internal Medicine Authors: Source Type: research
More News: Arthritis | Rheumatology